Symbols / PPBT $4.14 +0.73% Purple Biotech Ltd
PPBT Chart
About
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.33M |
| Enterprise Value | 7.63B | Income | -26.39M | Sales | — |
| Book/sh | 0.01 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | -6.47 | PEG | — |
| P/S | — | P/B | 827.98 | P/C | — |
| EV/EBITDA | -1094.33 | EV/Sales | — | Quick Ratio | 1.24 |
| Current Ratio | 1.27 | Debt/Eq | 2.53 | LT Debt/Eq | — |
| EPS (ttm) | -54.00 | EPS next Y | -0.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-13 08:00 | ROA | -15.97% |
| ROE | -124.46% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 929.46K |
| Shs Float | 1.84B | Short Float | 0.96% | Short Ratio | 0.45 |
| Short Interest | — | 52W High | 29.40 | 52W Low | 3.60 |
| Beta | -0.70 | Avg Volume | 12.77K | Volume | 10.64K |
| Target Price | $30.00 | Recom | None | Prev Close | $4.11 |
| Price | $4.14 | Change | 0.73% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2024-09-20 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2024-08-19 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-07 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-11-21 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-08-31 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-08-30 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-07-21 | init | JonesTrading | — → Buy | $8 |
| 2023-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-17 | reit | Chardan Capital | Buy → Buy | $11 |
| 2023-02-09 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-02-09 | reit | Chardan Capital | — → Buy | $11 |
| 2022-10-17 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2022-09-08 | init | Chardan Capital | — → Buy | $11 |
- Purple Biotech (PPBT) director details 3.09M shares and 2.95M options - Stock Titan Mon, 06 Apr 2026 20
- Purple Biotech Ltd (PPBT) Stock Price, Trades & News - gurufocus.com Fri, 03 Apr 2026 23
- Purple Biotech Ltd. (PPBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 03 Apr 2026 00
- Hot Trades Live - CMBM Stock - PPBT Stock - ERNA Stock - FUBO - FGL - TLIH - PFSA - VSEE - SPY [ce1360] - Fathom Journal Sat, 04 Apr 2026 19
- Purple Biotech stock soars after manufacturing milestone for tri-specific antibody - Investing.com Wed, 29 Oct 2025 07
- Purple Biotech halts two cancer drugs to push new 3-target antibody platform - Stock Titan Fri, 13 Mar 2026 07
- Purple Biotech (PPBT) CEO details RSUs and major stock options - Stock Titan ue, 31 Mar 2026 11
- Purple Biotech (NASDAQ: PPBT) unveils CAPTN-3 data on tumor regression and PD-1–resistant models - Stock Titan hu, 11 Dec 2025 08
- Purple Biotech CEO steps aside for health, shifts to dealmaking role - Stock Titan Fri, 13 Mar 2026 07
- Purple Biotech (PPBT) executive reports 9.25M shares plus multi-year options - Stock Titan Mon, 30 Mar 2026 20
- Purple Biotech uses AI to speed antibody drugs for solid tumors - Stock Titan Wed, 25 Mar 2026 07
- If You Invested $1,000 in Purple Biotech Ltd (PPBT) - Stock Titan Mon, 23 Mar 2026 08
- Purple Biotech (PPBT) director reports large RSU and option holdings - Stock Titan Fri, 27 Mar 2026 07
- Purple Biotech (PPBT) CFO details multi-million share options and RSUs - Stock Titan Mon, 30 Mar 2026 21
- Cancer immunotherapy company Purple Biotech keeps its Nasdaq listing - Stock Titan ue, 17 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
6.98
-35.43%
|
10.80
-51.49%
|
22.27
-1.47%
|
22.60
|
| Research And Development |
|
3.73
-51.04%
|
7.62
-55.27%
|
17.03
+4.38%
|
16.32
|
| Selling General And Administration |
|
2.98
+1.64%
|
2.94
-39.41%
|
4.84
-18.75%
|
5.96
|
| General And Administrative Expense |
|
2.98
+1.64%
|
2.94
-39.41%
|
4.84
-18.75%
|
5.96
|
| Salaries And Wages |
|
1.74
-13.88%
|
2.02
-45.40%
|
3.69
-20.41%
|
4.64
|
| Other Gand A |
|
1.25
+35.73%
|
0.92
-20.17%
|
1.15
-12.94%
|
1.32
|
| Other Operating Expenses |
|
0.06
-4.84%
|
0.06
-68.37%
|
0.20
+63.33%
|
0.12
|
| Total Expenses |
|
6.98
-35.43%
|
10.80
-51.49%
|
22.27
-1.47%
|
22.60
|
| Operating Income |
|
-6.98
+35.43%
|
-10.80
+51.49%
|
-22.27
+1.47%
|
-22.60
|
| Total Operating Income As Reported |
|
-27.46
-149.50%
|
-11.01
+50.59%
|
-22.27
+1.47%
|
-22.60
|
| EBITDA |
|
-26.25
-272.23%
|
-7.05
+64.25%
|
-19.72
+8.23%
|
-21.49
|
| Normalized EBITDA |
|
-7.49
+30.62%
|
-10.79
+54.53%
|
-23.73
-8.84%
|
-21.80
|
| Reconciled Depreciation |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| EBIT |
|
-26.45
-265.47%
|
-7.24
+63.67%
|
-19.92
+8.17%
|
-21.69
|
| Total Unusual Items |
|
-18.77
-602.28%
|
3.74
-6.62%
|
4.00
+1203.26%
|
0.31
|
| Total Unusual Items Excluding Goodwill |
|
-18.77
-602.28%
|
3.74
-6.62%
|
4.00
+1203.26%
|
0.31
|
| Special Income Charges |
|
-20.48
-10039.60%
|
-0.20
|
0.00
|
0.00
|
| Write Off |
|
20.48
+10039.60%
|
0.20
|
0.00
|
0.00
|
| Net Income |
|
-26.39
-264.45%
|
-7.24
+63.58%
|
-19.88
+8.25%
|
-21.67
|
| Pretax Income |
|
-26.49
-263.95%
|
-7.28
+63.56%
|
-19.98
+8.19%
|
-21.76
|
| Net Non Operating Interest Income Expense |
|
-0.75
-254.25%
|
-0.21
+87.58%
|
-1.71
-418.47%
|
0.54
|
| Interest Expense Non Operating |
|
0.04
-4.88%
|
0.04
-26.79%
|
0.06
-16.42%
|
0.07
|
| Net Interest Income |
|
-0.75
-254.25%
|
-0.21
+87.58%
|
-1.71
-418.47%
|
0.54
|
| Interest Expense |
|
0.04
-4.88%
|
0.04
-26.79%
|
0.06
-16.42%
|
0.07
|
| Interest Income Non Operating |
|
0.23
-12.69%
|
0.26
-45.15%
|
0.47
-10.90%
|
0.53
|
| Interest Income |
|
0.23
-12.69%
|
0.26
-45.15%
|
0.47
-10.90%
|
0.53
|
| Other Income Expense |
|
-18.77
-602.28%
|
3.74
-6.62%
|
4.00
+1203.26%
|
0.31
|
| Gain On Sale Of Security |
|
1.72
-56.40%
|
3.94
-1.57%
|
4.00
+1203.26%
|
0.31
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.49
-263.95%
|
-7.28
+63.56%
|
-19.98
+8.19%
|
-21.76
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.39
-264.45%
|
-7.24
+63.58%
|
-19.88
+8.25%
|
-21.67
|
| Net Income From Continuing And Discontinued Operation |
|
-26.39
-264.45%
|
-7.24
+63.58%
|
-19.88
+8.25%
|
-21.67
|
| Net Income Continuous Operations |
|
-26.49
-263.95%
|
-7.28
+63.56%
|
-19.98
+8.19%
|
-21.76
|
| Net Income Discontinuous Operations |
|
—
|
—
|
0.00
|
0.00
|
| Minority Interests |
|
0.11
+171.79%
|
0.04
-59.79%
|
0.10
+5.43%
|
0.09
|
| Normalized Income |
|
-7.62
+30.57%
|
-10.98
+54.04%
|
-23.88
-8.67%
|
-21.98
|
| Net Income Common Stockholders |
|
-26.39
-264.45%
|
-7.24
+63.58%
|
-19.88
+8.25%
|
-21.67
|
| Diluted EPS |
|
1,099.20
+2589.24%
|
-44.16
-396.16%
|
-8.90
+96.29%
|
-240.00
|
| Basic EPS |
|
1,099.20
+2589.24%
|
-44.16
-396.16%
|
-8.90
+96.29%
|
-240.00
|
| Basic Average Shares |
|
0.02
-85.36%
|
0.16
-92.59%
|
2.21
+2348.24%
|
0.09
|
| Diluted Average Shares |
|
0.02
-85.36%
|
0.16
-92.59%
|
2.21
+2348.24%
|
0.09
|
| Diluted NI Availto Com Stockholders |
|
-26.39
-264.45%
|
-7.24
+63.58%
|
-19.88
+8.25%
|
-21.67
|
| Depreciation Amortization Depletion Income Statement |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| Depreciation And Amortization In Income Statement |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| Depreciation Income Statement |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| Total Other Finance Cost |
|
0.94
+117.87%
|
0.43
-79.72%
|
2.12
+3092.96%
|
-0.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
17.57
-52.56%
|
37.04
-16.40%
|
44.30
-18.89%
|
54.62
|
| Current Assets |
|
9.87
+10.75%
|
8.91
-43.58%
|
15.79
-52.53%
|
33.26
|
| Cash Cash Equivalents And Short Term Investments |
|
9.57
+12.32%
|
8.52
-44.69%
|
15.41
-52.01%
|
32.11
|
| Cash And Cash Equivalents |
|
8.72
+17.78%
|
7.40
-48.92%
|
14.49
-3.60%
|
15.03
|
| Cash Financial |
|
—
|
—
|
14.49
-3.60%
|
15.03
|
| Other Short Term Investments |
|
0.86
-23.69%
|
1.12
+21.67%
|
0.92
-94.60%
|
17.08
|
| Receivables |
|
0.15
-43.64%
|
0.28
+34.15%
|
0.20
-79.44%
|
1.00
|
| Other Receivables |
|
0.15
-43.64%
|
0.28
+34.15%
|
0.20
-79.44%
|
1.00
|
| Prepaid Assets |
|
—
|
—
|
0.20
-79.44%
|
1.00
|
| Other Current Assets |
|
0.14
+25.69%
|
0.11
-36.26%
|
0.17
+17.12%
|
0.15
|
| Total Non Current Assets |
|
7.71
-72.61%
|
28.13
-1.35%
|
28.51
+33.46%
|
21.37
|
| Net PPE |
|
0.35
+20.14%
|
0.29
-38.72%
|
0.47
-31.09%
|
0.68
|
| Gross PPE |
|
0.35
+20.14%
|
0.29
-38.72%
|
0.47
-31.09%
|
0.68
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.22
+35.37%
|
0.16
-48.10%
|
0.32
-32.33%
|
0.47
|
| Other Properties |
|
0.12
+0.00%
|
0.12
-19.48%
|
0.15
-28.37%
|
0.21
|
| Goodwill And Other Intangible Assets |
|
7.36
-73.57%
|
27.84
-0.72%
|
28.04
+35.58%
|
20.68
|
| Other Intangible Assets |
|
7.36
-73.57%
|
27.84
-0.72%
|
28.04
|
—
|
| Investments And Advances |
|
—
|
—
|
—
|
0.00
|
| Other Investments |
|
—
|
—
|
—
|
0.00
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
7.91
+91.74%
|
4.13
-58.75%
|
10.01
+32.97%
|
7.52
|
| Current Liabilities |
|
7.75
+94.46%
|
3.99
-58.90%
|
9.70
+37.45%
|
7.06
|
| Payables And Accrued Expenses |
|
3.44
+29.68%
|
2.65
-62.04%
|
7.00
+1.91%
|
6.86
|
| Payables |
|
2.42
+31.46%
|
1.84
-56.31%
|
4.21
+48.59%
|
2.83
|
| Accounts Payable |
|
2.07
+42.27%
|
1.46
-58.81%
|
3.53
+65.67%
|
2.13
|
| Other Payable |
|
0.02
-69.23%
|
0.07
+22.64%
|
0.05
-41.76%
|
0.09
|
| Current Accrued Expenses |
|
1.03
+25.67%
|
0.82
-70.68%
|
2.79
-30.84%
|
4.03
|
| Employee Benefits |
|
0.16
+14.29%
|
0.14
-0.71%
|
0.14
-2.76%
|
0.14
|
| Current Debt And Capital Lease Obligation |
|
0.24
+33.33%
|
0.18
-2.66%
|
0.19
-3.09%
|
0.19
|
| Current Capital Lease Obligation |
|
0.24
+33.33%
|
0.18
-2.66%
|
0.19
-3.09%
|
0.19
|
| Other Current Liabilities |
|
4.07
+253.87%
|
1.15
-54.37%
|
2.52
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.16
+14.29%
|
0.14
-53.95%
|
0.30
-34.76%
|
0.47
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.16
-49.22%
|
0.32
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.16
-49.22%
|
0.32
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.16
+14.29%
|
0.14
-0.71%
|
0.14
-2.76%
|
0.14
|
| Stockholders Equity |
|
9.71
-70.44%
|
32.86
-3.94%
|
34.21
-27.08%
|
46.91
|
| Common Stock Equity |
|
9.71
-70.44%
|
32.86
-3.94%
|
34.21
-27.08%
|
46.91
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1,858.91
+259.47%
|
517.13
+104.90%
|
252.38
+36.56%
|
184.82
|
| Ordinary Shares Number |
|
1,858.91
+259.47%
|
517.13
+104.90%
|
252.38
+36.56%
|
184.82
|
| Treasury Shares Number |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
152.48
+3.29%
|
147.63
+10.85%
|
133.18
+5.36%
|
126.41
|
| Retained Earnings |
|
-171.08
-18.24%
|
-144.69
-5.27%
|
-137.45
-16.91%
|
-117.57
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.10
+0.00%
|
-0.10
-24.05%
|
-0.08
+24.04%
|
-0.10
|
| Minority Interest |
|
-0.06
-207.84%
|
0.05
-43.33%
|
0.09
-51.87%
|
0.19
|
| Other Equity Adjustments |
|
-0.10
+0.00%
|
-0.10
-24.05%
|
-0.08
+24.04%
|
-0.10
|
| Total Equity Gross Minority Interest |
|
9.66
-70.65%
|
32.91
-4.04%
|
34.30
-27.18%
|
47.10
|
| Total Capitalization |
|
9.71
-70.44%
|
32.86
-3.94%
|
34.21
-27.08%
|
46.91
|
| Working Capital |
|
2.11
-57.06%
|
4.92
-19.16%
|
6.09
-76.77%
|
26.20
|
| Invested Capital |
|
9.71
-70.44%
|
32.86
-3.94%
|
34.21
-27.08%
|
46.91
|
| Total Debt |
|
0.24
+33.33%
|
0.18
-47.86%
|
0.35
-31.84%
|
0.52
|
| Capital Lease Obligations |
|
0.24
+33.33%
|
0.18
-47.86%
|
0.35
-31.84%
|
0.52
|
| Net Tangible Assets |
|
2.35
-53.09%
|
5.02
-18.58%
|
6.16
-76.50%
|
26.23
|
| Tangible Book Value |
|
2.35
-53.09%
|
5.02
-18.58%
|
6.16
-76.50%
|
26.23
|
| Derivative Product Liabilities |
|
—
|
—
|
2.52
|
0.00
|
| Dueto Related Parties Current |
|
0.33
+2.52%
|
0.32
-48.87%
|
0.62
+2.14%
|
0.61
|
| Other Equity Interest |
|
28.41
-5.37%
|
30.02
-22.14%
|
38.55
+0.98%
|
38.18
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.66
+60.63%
|
-14.37
+27.89%
|
-19.93
-19.06%
|
-16.73
|
| Cash Flow From Continuing Operating Activities |
|
-5.66
+60.63%
|
-14.37
+27.89%
|
-19.93
-19.06%
|
-16.73
|
| Cash From Discontinued Operating Activities |
|
—
|
—
|
0.00
|
0.00
|
| Net Income From Continuing Operations |
|
-26.49
-263.95%
|
-7.28
+63.56%
|
-19.98
+8.19%
|
-21.76
|
| Depreciation Amortization Depletion |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| Depreciation |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| Depreciation And Amortization |
|
0.20
+9.14%
|
0.19
-5.58%
|
0.20
-1.99%
|
0.20
|
| Other Non Cash Items |
|
-0.97
+74.07%
|
-3.73
-62.42%
|
-2.29
-172.12%
|
-0.84
|
| Stock Based Compensation |
|
0.31
-46.91%
|
0.58
-68.96%
|
1.88
-22.26%
|
2.41
|
| Asset Impairment Charge |
|
20.48
+10039.60%
|
0.20
|
0.00
|
0.00
|
| Change In Working Capital |
|
0.81
+118.65%
|
-4.33
-1681.02%
|
0.27
-91.58%
|
3.25
|
| Change In Receivables |
|
—
|
—
|
—
|
0.31
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.31
|
| Change In Payables And Accrued Expense |
|
0.66
+114.79%
|
-4.43
-1816.28%
|
0.26
-91.20%
|
2.93
|
| Change In Payable |
|
0.66
+114.79%
|
-4.43
-1816.28%
|
0.26
-91.20%
|
2.93
|
| Change In Account Payable |
|
0.45
+121.68%
|
-2.08
-255.62%
|
1.33
+66.96%
|
0.80
|
| Change In Other Working Capital |
|
—
|
—
|
-0.16
-1572.73%
|
0.01
|
| Change In Other Current Assets |
|
0.15
+59.38%
|
0.10
-46.07%
|
0.18
-43.13%
|
0.31
|
| Investing Cash Flow |
|
0.63
+24.17%
|
0.51
-96.33%
|
13.88
-30.30%
|
19.91
|
| Cash Flow From Continuing Investing Activities |
|
0.63
+24.17%
|
0.51
-96.33%
|
13.88
-30.30%
|
19.91
|
| Cash From Discontinued Investing Activities |
|
—
|
—
|
—
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.00
|
0.00
+100.00%
|
-0.00
+88.46%
|
-0.03
|
| Purchase Of PPE |
|
-0.00
|
0.00
+100.00%
|
-0.00
+88.46%
|
-0.03
|
| Capital Expenditure |
|
-0.00
|
—
|
-0.00
+98.68%
|
-0.23
|
| Net Investment Purchase And Sale |
|
0.45
+137.57%
|
0.19
-98.87%
|
16.68
-15.84%
|
19.82
|
| Purchase Of Investment |
|
-0.01
|
—
|
—
|
—
|
| Sale Of Investment |
|
0.46
+142.33%
|
0.19
-98.87%
|
16.68
-15.84%
|
19.82
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-3.55
|
0.00
|
| Purchase Of Business |
|
0.00
|
0.00
+100.00%
|
-3.55
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.20
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
+100.00%
|
-0.20
|
| Financing Cash Flow |
|
6.33
-6.51%
|
6.77
+24.32%
|
5.45
+389.14%
|
1.11
|
| Cash Flow From Continuing Financing Activities |
|
6.33
-6.51%
|
6.77
+24.32%
|
5.45
+389.14%
|
1.11
|
| Net Issuance Payments Of Debt |
|
-0.22
-18.58%
|
-0.18
-8.93%
|
-0.17
-1.82%
|
-0.17
|
| Repayment Of Debt |
|
-0.22
-18.58%
|
-0.18
-8.93%
|
-0.17
-1.82%
|
-0.17
|
| Long Term Debt Payments |
|
-0.22
-18.58%
|
-0.18
-8.93%
|
-0.17
-1.82%
|
-0.17
|
| Net Long Term Debt Issuance |
|
-0.22
-18.58%
|
-0.18
-8.93%
|
-0.17
-1.82%
|
-0.17
|
| Net Common Stock Issuance |
|
3.15
-45.72%
|
5.81
+271.66%
|
1.56
+4.34%
|
1.50
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
4.24
+109.07%
|
2.03
-59.44%
|
5.00
|
0.00
|
| Net Other Financing Charges |
|
-0.82
+1.91%
|
-0.84
+6.07%
|
-0.89
-485.53%
|
-0.15
|
| Changes In Cash |
|
1.31
+118.48%
|
-7.08
-1090.59%
|
-0.59
-113.86%
|
4.29
|
| Effect Of Exchange Rate Changes |
|
0.01
+275.00%
|
-0.00
-107.41%
|
0.05
+135.29%
|
-0.15
|
| Beginning Cash Position |
|
7.40
-48.92%
|
14.49
-3.60%
|
15.03
+38.02%
|
10.89
|
| End Cash Position |
|
8.72
+17.78%
|
7.40
-48.92%
|
14.49
-3.60%
|
15.03
|
| Free Cash Flow |
|
-5.66
+60.61%
|
-14.37
+27.91%
|
-19.93
-17.48%
|
-16.96
|
| Common Stock Issuance |
|
3.15
-45.72%
|
5.81
+271.66%
|
1.56
+4.34%
|
1.50
|
| Interest Paid CFF |
|
-0.02
+47.73%
|
-0.04
+21.43%
|
-0.06
+16.42%
|
-0.07
|
| Interest Received CFI |
|
0.19
-41.88%
|
0.32
-57.62%
|
0.76
+133.02%
|
0.32
|
| Issuance Of Capital Stock |
|
3.15
-45.72%
|
5.81
+271.66%
|
1.56
+4.34%
|
1.50
|
| Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Cash Flow From Discontinued Operation |
|
—
|
—
|
—
|
—
|
| Cash From Discontinued Financing Activities |
|
—
|
—
|
—
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|